The BGT2025 Annual Meeting is buzzing with exciting updates and discussions on precision oncology, biomarkers, and targeted therapies across solid cancers. Leading experts, including Tanios Bekaii-Saab, Vivek Subbiah, Emil Lou, and Stephen Liu, are diving into key topics like biomarker discovery, actionable alterations in cancers like hepatobiliary and pancreatic, and the evolving role of AI in cancer research. With lively panels, including one led by Ishwaria Subbiah on fellow education and needs, the event is a hub for groundbreaking insights and collaboration in the fight against cancer.
Chadi Nabhan, Chief Medical Officer and Head of Strategy at Ryght AI, Inc, shared on X:
“The “King” of precision oncology as named by Tanios Bekaii-Saab – the Vivek Subbiah is in da house. BGT2025 Annual Meeting.”
Chadi Nabhan also shared:
“So good to see Neeraj Agarwal, Rafeh Naqash and many colleagues at the annual #BGT2025 meeting – great content and discussions. We cannot locate Balazs Halmos.”
Chadi Nabhan adding:
“The BGT2025 is about to kickoff – updates soon on Biomarkers, Genes, and Targets across all solid cancers.”
He also shared:
“The amazing Ishwaria Subbiah moderating a fellows’ panel to better understand their pain points, education and needs.
Balazs Halmos and Petros Grivas still missing but Vivek Subbiah is in the building.”
Stephen Liu, Chief, Division of Hematology & Oncology at Georgetown Lombardi Comprehensive Cancer Center, shared on X:
“Learning biomarkers in GI oncology from Tanios Bekaii-Saab at BGT2025. And panel discussion included birthday wishes for Cathy Eng from Chadi Nabhan, Bassel El-Rayes and Al Benson.”
Later Stephen Liu shared:
“Update on biomarkers in hepatobiliary cancers from Emil Lou at BGT2025 with Tanios Bekaii-Saab, Bassel El-Rayes. Pancreatic cancer moves from no actionable alterations to one rich in targets once we can act on KRAS.”
Emil Lou, Professor with Tenure at University of MinnesotaUniversity of Minnesota, shared on X:
“Highly spirited discussion at BGT2025 on biomarker discovery and advancement of biomarker-targeting drugs; the grandfather of cancer biomarkers – EGFR in non-small cell lung cancer – came up as example for FDA withdrawal then restored indication after biomarker validation.”
Emil Lou also shared:
“Thank you Chadi Nabhan for the invitation to discuss Hepatobiliary Cancers and opportunities for improvement and progress re: Biomarkers, Genes, and Targets at BGT2025 with esteemed Tanios Bekaii-Saab and Bassel El-Rayes. And yes, AI too has room for improvement in this field.”
See other insights from GI Oncology on OncoDaily.